A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma

Anti-Cancer Drugs

Volumn 19, Issue 2, 2008, Pages 133-142

  Sonabend, Adam M ^a   Velicu, Simona ^a   Ulasov, Ilya V ^a   Han, Yu ^a   Tyler, Betty ^b   Brem, Henry ^b   Matar, Majed M ^c   Fewell, Jason G ^c   Anwer, Khursheed ^c   Lesniak, MacIej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Expression Genetics Inc   (United States)

Author keywords

Brain tumor; Gene therapy; Glioma; Immunotherapy; Interleukin 12; Polymer

Indexed keywords

CARMUSTINE; DNA; GLYCOL; INTERLEUKIN 12; METHOXYPOLYETHYLENEGLYCOL; POLYETHYLENEIMINE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL STUDY; GENE EXPRESSION; GENE THERAPY; GLIOMA; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TRANSGENE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; CHOLESTEROL; COS CELLS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENE THERAPY; GLIOMA; INJECTIONS; INTERLEUKIN-12; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, INBRED C57BL; PLASMIDS; POLYETHYLENE GLYCOLS; POLYMERS; TRANSFECTION; TRANSGENES;

EID: 37849052026     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f24017     Document Type: Article

References (69)

1. Wood GW, Morantz RA. In vitro reversal of depressed T-lymphocyte function in the peripheral blood of brain tumor patients. J Natl Cancer Inst 1982; 68:27-33.
2. Wood GW, Morantz RA. Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J Neurooncol 1983; 1:87-94.
3. Yamasaki T, Handa H, Yamashita J, Namba Y, Hanaoka M. Characteristic immunological responses to an experimental mouse brain tumor. Cancer Res 1983; 43:4610-4617.
4. + regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006; 105:430-437.
5. + regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncol 2006; 8:234-243.
6. + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007; 83:145-152.
7. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006; 54:526-535.
8. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66:3294-3302.
9. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006; 12:4294-4305.
10. + regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121:95-105.
11. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-oncol 2006; 8:261-279.
12. + T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res 2006; 12:7306-7315.
13. Grauer O, Poschl P, Lohmeier A, Adema GJ, Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neurooncol 2007; 82:151-161.
14. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001; 52:401-410.
15. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995; 21:128-151.
16. Lauro GM, Di Lorenzo N, Grossi M, Maleci A, Guidetti B. Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol (Berl) 1986; 69:278-282.
17. Nakano Y, Kuroda E, Kito T, Yokota A, Yamashita U. Induction of macrophagic prostaglandin E2 synthesis by glioma cells. J Neurosurg 2006; 104:574-582.
18. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001; 50:515-522.
19. Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front Biosci 2004; 9:3124-3136.
20. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168:4772-4780.
21. Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 2003; 13:343-351.
22. Lesniak MS, Langer R, Brem H. Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 2001; 1:210-216.
23. Ehtesham M, Stevenson CB, Thompson RC. Stem cell therapies for malignant glioma. Neurosurg Focus 2005; 19:E5.
24. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002; 62:5657-5663.
25. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90:1115-1124.
26. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-4979.
27. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842-847.
28. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10:967-972.
29. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005; 12:585-598.
30. Takeuchi E, Yanagawa H, Suzuki Y, Shinkawa K, Ohmoto Y, Bando H, et al. IL-12-induced production of IL-10 and interferon-gamma by mononuclear cells in lung cancer-associated malignant pleural effusions. Lung Cancer 2002; 35:171-177.
31. Verma V, Sharma V, Shrivastava SK, Nadkarni JJ. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients. J Exp Clin Cancer Res 2000; 19:367-374.
32. Ahn WS, Bae SM, Kim TY, Kim TG, Lee JM, Namkoong SE, et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003; 14:1389-1399.
33. Keke F, Hongyang Z, Hui Q, Jixiao L, Jian C. A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother Radiopharm 2004; 19:649-657.
34. Suzuki S, Umezu Y, Saijo Y, Satoh G, Abe Y, Satoh K, et al. Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J Exp Med 1998; 185:223-226.
35. Oshikawa K, Ishii Y, Hamamoto T, Sugiyama Y, Kitamura S, Kagawa Y. Particle-mediated gene transfer of murine interleukin-12 cDNA suppresses the growth of Lewis lung carcinoma. In Vivo 1999; 13:397-402.
36. Pressley JS, Elgert KD. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12. Cancer Invest 2006; 24:351-359.
37. Tamura T, Nishi T, Goto T, Takeshima H, Ushio Y, Sakata T. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res 2003; 23:1173-1179.
38. Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, et al. Two phase I studies of low dose recombinant human IL-12 with melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 3:7.
39. Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55:807-813.
40. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6:1678-1692.
41. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003; 21:2564-2573.
42. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4:1183-1191.
43. Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 vs. interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001; 21:257-263.
44. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22:1389-1397.
45. Imagawa Y, Satake K, Kato Y, Tahara H, Tsukuda M. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model. Auris Nasus Larynx 2004; 31:239-245.
46. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87:3877-3882.
47. Desaknai S, Lumniczky K, Hidvegi EJ, Hamada H, Safrany G. Brain tumor treatment with IL-2 and IL-12 producing autologous cancer cell vaccines. Adv Exp Med Biol 2001; 495:369-372.
48. DiMeco F, Rhines LD, Hanes J, Tyler BM, Brat D, Torchiana E, et al. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J Neurosurg 2000; 92:419-427.
49. Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC. Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 1998; 42:850-856 (discussion 856-857).
50. Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villarreal LP, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002; 9:9-15.
51. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000; 97:2208-2213.
52. Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC, Rainov NG. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene: a phase I/II clinical protocol. J Neurooncol 2003; 64:147-154.
53. Roy EJ, Gawlick U, Orr BA, Rund LA, Webb AG, Kranz DM. IL-12 treatment of endogenously arising murine brain tumors. J Immunol 2000; 165:7293-7299.
54. Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, Tanaka R, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing semliki forest virus-mediated interleukin-12. J Neurosurg 2002; 97:611-618.
55. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27:452-459.
56. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther 2001; 4:130-138.
57. Maheshwari A, Mahato RI, McGregor J, Han S, Samlowski WE, Park JS, et al. Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol Ther 2000; 2:121-130.
58. Quezada A, Larson J, French M, Ponce R, Perrard J, Durland R, et al. Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol 2004; 56:177-185.
59. Fewell JG, Matar M, Slobodkin G, Han SO, Rice J, Hovanes B, et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release 2005; 109:288-298.
60. Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 2004; 66:351-360.
61. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5:79-88.
62. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997; 39:383-389.
63. Domb A, Langer R. Polyanhydrides: I. Preparation of high molecular weight polymers. J Polym Sci 1987; 25:3373.
64. Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J Control Release 2003; 87:177-186.
65. Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74:441-446.
66. Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE, Yang NS, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56:3399-3403.
67. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 2003; 26:107-116.
68. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 2000; 47:117-124.
69. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003; 89:1172-1179.